Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with ...

HOUSTON, TX, July 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the "Company" or "Nexalin") today announced the closing of its previously announced public offering of 3,000,000 shares of common stock at public offering price of $1.75. Gross proceeds, before deducting placement agent fees and other offering expenses were approximately $5,250,000. The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-279684) (the "R ...

Nexalin Technology (NASDAQ:NXL) stock is down on Friday after the medical device company priced a public offering of its shares. Nexalin Technology is selling 3 million shares of NXL stock for $1.75 each in this public offering. This has the company expecting gross proceeds from the offering to come in at $5.25 million. Nexalin Technology notes that Maxim Group LLC is acting as the sole placement agent for the offering. The company is also expecting this offering to close on Monday. What This Means for NXL ...

Company Overview - Nexalin Technology, Inc. designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing bioelectronic medical technology to treat mental health issues [4]. Public Offering Details - The company announced a public offering of 3,000,000 shares of common stock at a public offering price of $1.75, expecting gross proceeds of approximately $5,250,000 before deducting fees and expenses [3][6]. Product Information - Nexalin's neurostimulation devices are designed to be non-invasive and undetectable, targeting deep structures in the mid-brain associated with mental health disorders. The next-generation devices are believed to enhance patient response without adverse side effects [4]. Regulatory and Compliance - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 27, 2024, and the final prospectus will be filed with the SEC [8].

The securities described above were offered pursuant to a registration statement on Form S-1, as amended (File No. 333-279684) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission (the "SEC") on June 27, 2024. The offering was made only by means of a prospectus which is a part of the Registration Statement. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus relating to this offering may be obtained from Max ...

HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW))) (the "Company" or "Nexalin") today announced positive results of a clinical study designed to evaluate the feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation (tACS) as an add-on treatment for the symptoms of major depressive disorder (MDD), also known as clinical depression, a mental health condition that affects mood, behavior, appetite, and sleep. The results of the st ...

The Gen-2 and Gen-3 medical device reflects the state-of-the-art development of Nexalin's Deep Intracranial Frequency Stimulation (DIFS®) technology, and a significant advancement to the predecessor Gen-1 system. The Company's new neuro-technology marks a digital breakthrough in electrical waveforms to provide a deep undetectable non-invasive brain stimulation technique that is designed to be safe, risk-free and highly effective. The Gen-2 and Gen-3 stimulation technique relies on the placement of strategic ...

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin's future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management "believes", "expects", "anticipates", "plans", "intends" and similar expressions) should be con ...

"Brazil is an important market as it represents the 9th largest economy in the world with a population in excess of 215 million. Among this population, more than 35 million are afflicted with mental health disorders. Moreover, this approval is an important springboard into other markets within South America. We are rapidly advancing discussions with a key distributor in this market and look forward to providing further updates." Recent NXL Stock Movement Following this news, shares of NXL stock jumped 121% ...

Mark White, CEO of Nexalin Technology, stated, "We are pleased to announce approval to sell our Gen-2 neurostimulation device in Brazil, which represents our second regulatory approval outside of China since the start of this year. Brazil is an important market as it represents the 9th largest economy in the world with a population in excess of 215 million. Among this population, more than 35 million are afflicted with mental health disorders. Moreover, this approval is an important springboard into other m ...